摘要
目的:基于气道IL-17/IL-23炎症介质轴,探讨人参皂苷Rg1对PM2.5哮喘大鼠肺损伤保护机制。方法:采集并分离交通相关大气细颗粒物PM2.5,利用卵白蛋白致敏和激发建立幼龄哮喘大鼠模型,再给予PM2.5气管滴注建立PM2.5哮喘肺损伤模型,采用酶联免疫吸附试验(ELISA)法测定血清和肺泡灌洗液IL-17a、IL-6、IL-23、TGF-β_(1)含量,RT-PCR检测RORγt mRNA表达,并行肺组织病理和电镜分析。结果:成功建立PM2.5气管滴注哮喘大鼠模型;哮喘大鼠模型血清和肺泡灌洗液IL-17a、IL-6、IL-23、TGF-β_(1)表达量增大(P<0.01),肺组织RORγt mRNA表达量增加(P<0.01);经PM2.5气管滴注后,模型组大鼠血清和肺泡灌洗液IL-17a、IL-6、IL-23、TGF-β_(1)含量进一步增加,RORγt mRNA表达量进一步上升(P<0.01);经皂苷Rg1干预后,呈现剂量依赖性下调血清和肺泡灌洗液IL-17a、IL-6、IL-23、TGF-β_(1)水平,下调RORγt mRNA表达量。结论:人参皂苷Rg1呈剂量依赖性改善PM2.5致哮喘大鼠肺气道炎症反应、改善肺损伤。
Objective:Based on the airway IL-17/IL-23 inflammatory factor axis,to explore the protective mechanism of Ginsenoside Rg1 on lung injury in PM2.5 asthmatic rats.Methods:PM2.5 was isolated and sensitized by ovalbumin,and then PM2.5 was intratracheal instilled to establish PM2.5 asthmatic lung injury model.The levels of IL-17a,IL-6,IL-23 and TGF-β_(1) in serum and BALF were measured by ELISA.The expression of RORγt mRNA was detected by RT-PCR,and the lung tissue pathology and electron microscopy were analyzed.Results:The asthmatic rat model of PM2.5 was established successfully;The expression of IL-17a,IL-6,IL-23 and TGF-β_(1) in serum and BALF of asthmatic rats increased(P<0.01),and the expression of RORγt mRNA in lung tissue increased(P<0.01);After PM2.5 intratracheal instillation,the contents of IL-17a,IL-6,IL-23 and TGF-β_(1) in serum and BALF of model group were further increased,and the expression of RORγt mRNA was further increased(P<0.01);After intervention with saponin Rg1,IL-17a,IL-6,IL-23,TGF-β_(1) in serum and BALF were decreased in a dose-dependent manner,and RORγt mRNA expression was down regulated.Conclusion:Ginsenoside Rg1 can improve airway inflammation and lung injury induced by PM2.5 in a concentration dependent manner.
作者
周亚兵
蒋思韵
王利维
华丽
ZHOU Yabing;JIANG Siyun;WANG Liwei;HUA Li(Xinhua Hospital,Shanghai Jiaotong University,Shanghai 200092,China)
出处
《世界中医药》
CAS
2021年第10期1520-1525,共6页
World Chinese Medicine
基金
国家临床重点专科项目(ZJ0901EK013)
上海市自然科学基金项目(14140903000)
上海市科委2020年度“科技创新行动计划”医学创新研究专项(20Y21900500)
上海市十三五临床重点专科(中医专业)项目(SHSLCZDZK04103)。